The role of endogenous opioid peptides in the antinociceptive effect of 15-deoxy(Δ12,14)-prostaglandin J2 in the temporomandibular joint.

[1]  Mariana Silva Quinteiro,et al.  15-deoxy-Δ12,14-prostaglandin J2 reduces albumin-induced arthritis in temporomandibular joint of rats. , 2014, European journal of pharmacology.

[2]  M. Kojima,et al.  Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone attenuates inflammatory pain through the induction of heme oxygenase-1 in macrophages , 2013, PAIN®.

[3]  J. Clemente-Napimoga,et al.  The indirect antinociceptive mechanism of 15d‐PGJ2 on rheumatoid arthritis‐induced TMJ inflammatory pain in rats , 2012, European journal of pain.

[4]  M. Napimoga,et al.  Exogenous Administration of 15d-PGJ2–Loaded Nanocapsules Inhibits Bone Resorption in a Mouse Periodontitis Model , 2012, The Journal of Immunology.

[5]  M. Napimoga,et al.  15d-PGJ2-loaded in nanocapsules enhance the antinociceptive properties into rat temporomandibular hypernociception. , 2012, Life sciences.

[6]  F. Cunha,et al.  Stimulation of peripheral Kappa opioid receptors inhibits inflammatory hyperalgesia via activation of the PI3Kγ/AKT/nNOS/NO signaling pathway , 2012, Molecular pain.

[7]  C. Stein,et al.  Modulation of Peripheral Sensory Neurons by the Immune System: Implications for Pain Therapy , 2011, Pharmacological Reviews.

[8]  Y. Surh,et al.  15-Deoxy-Δ¹²,¹⁴-prostaglandin J₂, an electrophilic lipid mediator of anti-inflammatory and pro-resolving signaling. , 2011, Biochemical pharmacology.

[9]  L. Roberts,et al.  Isoprostane generation and function. , 2011, Chemical reviews.

[10]  E. Inada,et al.  The Macrophage-Mediated Effects of the Peroxisome Proliferator-Activated Receptor-Gamma Agonist Rosiglitazone Attenuate Tactile Allodynia in the Early Phase of Neuropathic Pain Development , 2011, Anesthesia and analgesia.

[11]  B. Cairns.  Pathophysiology of TMD pain--basic mechanisms and their implications for pharmacotherapy. , 2010, Journal of oral rehabilitation.

[12]  M. Teixeira,et al.  Morphine peripheral analgesia depends on activation of the PI3Kγ/AKT/nNOS/NO/KATP signaling pathway , 2010, Proceedings of the National Academy of Sciences.

[13]  S. Vieira,et al.  Activation of peripheral κ/δ opioid receptors mediates 15-deoxy-Δ12,14-prostaglandin J2 induced-antinociception in rat temporomandibular joint , 2009, Neuroscience.

[14]  M. Napimoga,et al.  Gonadal hormones decrease temporomandibular joint kappa-mediated antinociception through a down-regulation in the expression of kappa opioid receptors in the trigeminal ganglia. , 2009, European journal of pharmacology.

[15]  O. Pol,et al.  Peripheral antinociceptive effects of mu- and delta-opioid receptor agonists in NOS2 and NOS1 knockout mice during chronic inflammatory pain. , 2009, European journal of pharmacology.

[16]  Ranjit S. Chima,et al.  Ciglitazone ameliorates lung inflammation by modulating the inhibitor &kgr;B protein kinase/nuclear factor-&kgr;B pathway after hemorrhagic shock , 2008, Critical care medicine.

[17]  F. Cunha,et al.  Crucial role of neutrophils in the development of mechanical inflammatory hypernociception , 2008, Journal of leukocyte biology.

[18]  F. Cunha,et al.  15d-Prostaglandin J2 Inhibits Inflammatory Hypernociception: Involvement of Peripheral Opioid Receptor , 2008, Journal of Pharmacology and Experimental Therapeutics.

[19]  T. Kawai,et al.  Peroxisome Proliferator-Activated Receptor-γ Ligand, 15-Deoxy-Δ12,14-Prostaglandin J2, Reduces Neutrophil Migration via a Nitric Oxide Pathway1 , 2008, The Journal of Immunology.

[20]  A. Lash,et al.  The PPAR gamma agonist Pioglitazone improves anatomical and locomotor recovery after rodent spinal cord injury , 2007, Experimental Neurology.

[21]  D. Resnick,et al.  Thiazolidinedione Class of Peroxisome Proliferator-Activated Receptor γ Agonists Prevents Neuronal Damage, Motor Dysfunction, Myelin Loss, Neuropathic Pain, and Inflammation after Spinal Cord Injury in Adult Rats , 2007, Journal of Pharmacology and Experimental Therapeutics.

[22]  K. Morimura,et al.  Expression of peroxisome proliferator-activated receptor-gamma in macrophage suppresses experimentally induced colitis. , 2007, American journal of physiology. Gastrointestinal and liver physiology.

[23]  C. Cahill,et al.  Anti-allodynic effects of peripheral delta opioid receptors in neuropathic pain , 2007, Pain.

[24]  D. Feinstein,et al.  Peroxisome proliferator‐activated receptor‐γ agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type‐2 diabetic rodents , 2006, Journal of neurochemistry.

[25]  F. Cunha,et al.  Hypernociceptive role of cytokines and chemokines: targets for analgesic drug development? , 2006, Pharmacology & therapeutics.

[26]  M. Rossi,et al.  Nitric oxide inhibits neutrophil migration by a mechanism dependent on ICAM-1: role of soluble guanylate cyclase. , 2006, Nitric oxide : biology and chemistry.

[27]  O. Hurtado,et al.  Rosiglitazone and 15-deoxy-Δ12,14-prostaglandin J2 Cause Potent Neuroprotection after Experimental Stroke through Noncompletely Overlapping Mechanisms , 2006, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[28]  G. Landreth,et al.  Peroxisome proliferator-activated receptor-γ ligands reduce inflammation and infarction size in transient focal ischemia , 2005, Neuroscience.

[29]  Timothy J. Burroughs,et al.  15-DEOXY-Δ12,14-PROSTAGLANDIN J2 (15D-PGJ2), A PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR γ LIGAND, REDUCES TISSUE LEUKOSEQUESTRATION AND MORTALITY IN ENDOTOXIC SHOCK , 2005 .

[30]  T. Herdegen,et al.  The intracerebral application of the PPARγ‐ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain , 2005, The European journal of neuroscience.

[31]  T. Mayadas,et al.  Neutrophil β2 integrins: moderators of life or death decisions , 2005 .

[32]  B. Zingarelli,et al.  PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-γ IS A NEW THERAPEUTIC TARGET IN SEPSIS AND INFLAMMATION , 2005, Shock.

[33]  F. Rice,et al.  CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[34]  C. Parada,et al.  Sexual dimorphism in the antinociception mediated by kappa opioid receptors in the rat temporomandibular joint , 2004, Neuroscience Letters.

[35]  Tomohiro Kato,et al.  A Potential Role of 15-Deoxy-Δ12,14-prostaglandin J2 for Induction of Human Articular Chondrocyte Apoptosis in Arthritis* , 2004, Journal of Biological Chemistry.

[36]  R. Reszka,et al.  Tissue Monocytes/Macrophages in Inflammation: Hyperalgesia versus Opioid-mediated Peripheral Antinociception , 2004, Anesthesiology.

[37]  N. Patel,et al.  Reduction in the evolution of murine type II collagen-induced arthritis by treatment with rosiglitazone, a ligand of the peroxisome proliferator-activated receptor gamma. , 2003, Arthritis and rheumatism.

[38]  E. Mazzon,et al.  The cyclopentenone prostaglandin 15‐deoxy‐Δ12,14‐ PGJ2 attenuates the development of colon injury caused by dinitrobenzene sulphonic acid in the rat , 2003, British journal of pharmacology.

[39]  I. Duarte,et al.  The kappa-opioid agonist (+/-)-bremazocine elicits peripheral antinociception by activation of the L-arginine/nitric oxide/cyclic GMP pathway. , 2002, European journal of pharmacology.

[40]  C. Parada,et al.  Development of a behavioral model of TMJ pain in rats: the TMJ formalin test , 2001, PAIN.

[41]  W. Wahli,et al.  Peroxisome proliferator-activated receptors: insight into multiple cellular functions. , 2000, Mutation research.

[42]  Y. Cury,et al.  delta-opioid receptors and nitric oxide mediate the analgesic effect of Crotalus durissus terrificus snake venom. , 2000, European journal of pharmacology.

[43]  Christopher K. Glass,et al.  The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation , 1998, Nature.

[44]  J. Auwerx,et al.  Peroxisome proliferator-activated receptors, orphans with ligands and functions. , 1997, Current opinion in lipidology.

[45]  A. Hassan,et al.  Local upregulation of corticotropin-releasing hormone and interleukin-1 receptors in rats with painful hindlimb inflammation. , 1996, European journal of pharmacology.

[46]  S. Ferreira,et al.  The molecular mechanism of action of peripheral morphine analgesia: stimulation of the cGMP system via nitric oxide release. , 1991, European journal of pharmacology.

[47]  J. Rosland.  The formalin test in mice: the influence of ambient temperature , 1991, Pain.

[48]  M. Zimmermann,et al.  Ethical guidelines for investigations of experimental pain in conscious animals , 1983, Pain.

[49]  S. D. De Rossi.  Orofacial pain: a primer. , 2013, Dental clinics of North America.

[50]  B. Sessle.  Peripheral and central mechanisms of orofacial inflammatory pain. , 2011, International review of neurobiology.

[51]  S. Jader,et al.  モルヒネの末梢鎮痛はPI3Kγ/AKT/nNOS/NO/KATPシグナリング経路の活性化に依存する , 2010 .

[52]  T. Mayadas,et al.  Neutrophil beta2 integrins: moderators of life or death decisions. , 2005, Trends in immunology.